Phase II Study to Evaluate the Effectiveness of EVT 302 in Smoking Cessation.

NCT00738595 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Smoking Cessation

Interventions

DRUG: EVT 302
DRUG: Placebo
DRUG: EVT 302 plus open label Nicotine replacement
DRUG: Placebo plus open label Nicotine Replacement

Sponsor

Evotec Neurosciences GmbH

Collaborators

[object Object]
[object Object]